Prosecution Insights
Last updated: November 20, 2026
Application No. 18/819,423

IMIDAZOLE-BASED POLYIMIDE MEMBRANES FOR SOUR NATURAL GAS SEPARATION

Final Rejection §102§103
Filed
Aug 29, 2024
Examiner
OLADAPO, TAIWO
Art Unit
1771
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Saudi Arabian Oil Company
OA Round
2 (Final)
53%
Grant Probability
Moderate
3-4
OA Rounds
11m
Est. Remaining
65%
With Interview

Examiner Intelligence

Grants 53% of resolved cases
53%
Career Allowance Rate
630 granted / 1183 resolved
-11.7% vs TC avg
Moderate +12% lift
Without
With
+11.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
64 currently pending
Career history
1275
Total Applications
across all art units

Statute-Specific Performance

§101
2.1%
-37.9% vs TC avg
§103
55.1%
+15.1% vs TC avg
§102
14.6%
-25.4% vs TC avg
§112
16.4%
-23.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1183 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . The amendment dated 08/12/2026 has been considered and entered. The amendment changes Ar1 to be benzene with 3 or 4 methyl groups attached which Zhang et al. (CN 114797507A) does not teach, thus overcoming the previous rejections, now withdrawn. However, the rejections in view of Wang et al. (CN 117018896A) are not overcome and thus maintained. Claim Rejections - 35 USC § 102/103 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1 – 25 are rejected under 35 U.S.C. 102(a)(1) as anticipated by Wang et al. (CN 117018896A) or, in the alternative, under 35 U.S.C. 103 as obvious over Wang et al. (CN 117018896A) In regard to claim 1, Wang teaches polyimide membrane (abstract). The polyimide polymer has a structure of a formula a), wherein in the structure, R1 can be a trimethyl phenyl structure, R2 can be a phenyl benzimidazole structure, with m and n each ranging from 1 to 1000 [0013 – 0017; claim 3]. The structure is analogous to the claimed structures, when in the structures of the claim, Ra is CH3 or CF3, m is 1 or 3, X is O and Ar1 to Ar5 are selected from the groups provided in the claims. [0013 – 0017]. The structures are analogous which would make the claims quickly envisaged or would at least be obvious. In regard to claims 2 – 20, 22, Wang teaches the polymer having he claimed limitations as previously stated. In regard to claim 21, Wang teaches the polymer having a similar structure with 3 methyl groups attached to the bridging phenyl ring rather than 4 methyl groups as claimed. Due to structural similarity, the claimed structural variation would have been obvious. A prima facie case of obviousness may be made when chemical compounds have very close structural similarities and similar utilities. “An obviousness rejection based on similarity in chemical structure and function entails the motivation of one skilled in the art to make a claimed compound, in the expectation that compounds similar in structure will have similar properties.” In rePayne, 606 F.2d 303, 313, 203 USPQ 245, 254 (CCPA 1979). See In rePapesch, 315 F.2d 381, 137 USPQ 43 (CCPA 1963) and In reDillon, 919 F.2d 688, 16 USPQ2d 1897 (Fed. Cir. 1991). In regard to claim 23, Wang teaches the polymer having the m and n repeat units each of from 1 to 1000 which would provide molecular weights of the claim. Wang teaches molecular weights of 90,000 to 150,000 g/mol [0023]. In regard to claim 24, Wang teaches the membrane having the polymer as previously stated. In regard to claim 25, Wang teaches the membrane which comprises the polymer and a metal organic framework at a ratio of from 1:0.05-0.4 and thus allows for the presence of the polymer in the claimed amounts [0010]. Allowable Subject Matter Claim 26 is allowed. The following is a statement of reasons for the indication of allowable subject matter: Zhang et al. (CN 114797507A) teaches membrane separation process having the claimed polymer but fails to particularly recite the combination of the claimed monomers or the concentration of the monomeric compounds as claimed. Response to Arguments Applicant's arguments have been fully considered but they are not persuasive. Applicant argues that Wang provides no teaching or guidance to combine the claimed structures to provide membrane materials exhibiting the properties of the claimed membrane. The argument is not persuasive. Wang teach membranes having the structures of formulas 1 and 2 of the claims and would be expected to have similar properties of the claimed polymer. Applicant argues that the claimed membrane recites superior and unexpectedly improved properties of permeability and selectivity over the prior art. The argument is not persuasive. The inventive examples are not commensurate in scope with the claims. While the claims, except for claim 26, do not limit the ratio of the monomers of formulas I and II, the inventive examples are drawn to ratios of 1:3 which does not support the breadth of the claims. While the claims allow for myriads of compounds providing the limitations of each of formulas I and II, the inventive examples are drawn to specific compounds, which does not support the breadth of the claims. While the claims, except for claim 26, are drawn to polymers, the inventive examples are drawn to membranes, which does not support the breadth of the claims. While the method of claim 26 allows for natural gas having 1 to 30% of CO2 and 1 to 40% of H2S, the inventive examples are drawn to process requiring specific unspecified concentrations of the CO2 and the H2S which does not support the breadth of the claims. The results are not persuasive. The results provide diffusivity values and solubility values for the comparative examples that overlap those of the inventive examples in Tables 3 and 4 and thus fail to demonstrate the alleged superior and unexpected results. Thus, applicant fails to provide inventive examples that are commensurate in scope with the claims and demonstrates unexpected results sufficient to rebut the case of obviousness. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to TAIWO OLADAPO whose telephone number is (571)270-3723. The examiner can normally be reached 8-5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Prem Singh can be reached at 571-272-6381. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /TAIWO OLADAPO/Primary Examiner, Art Unit 1771
Read full office action

Prosecution Timeline

Aug 29, 2024
Application Filed
May 15, 2026
Non-Final Rejection mailed — §102, §103
Aug 12, 2026
Response Filed
Oct 15, 2026
Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799418
FUEL COMPOSITION FOR COMBUSTION
2y 9m to grant Granted Nov 17, 2026
Patent 12790560
LUBRICATING OIL COMPOSITIONS FOR HYDROGEN FUELED ENGINES FOR REDUCED PRE-IGNITION
1y 8m to grant Granted Nov 10, 2026
Patent 12781150
LUBRICATING OIL COMPOSITION
1y 10m to grant Granted Nov 03, 2026
Patent 12760235
OIL-IN-WATER EMULSIONS
3y 4m to grant Granted Oct 13, 2026
Patent 12760437
Self-Lubricating Coating, Fabrication Method, and Electrical Contact
2y 8m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
53%
Grant Probability
65%
With Interview (+11.9%)
3y 1m (~11m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1183 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month